5th International Symposium on Minimal Residual Cancer

Last Modified: May 11, 2005

Conference Dates: September 11-14, 2005
Conference Location: Fairmont Hotel, San Francisco, CA

Sponsoring Group: International Symposium on Minimal Residual Cancer

Conference Web Page URL: www.ismrc.org

Topics Covered:

    The Detection of Microscopic Disease in Breast Cancer: a Paradigm for Other Solid Tumors
  • ICC- and PCR-based strategies
  • Microscopic disease in sentinel nodes
  • Microscopic disease in bone marrow: when to detect?
  • Circulating tumor cells (CTCs): a prognostic or predictive factor?
  • MRD in bone marrow: future directions:
  • MRD in blood: future directions
  • Panel discussion: Cooperation between USA and EU for the development and implementation of methods of detection of MRD in breast cancer
    The Detection of Microscopic Disease in Solid Malignancies
  • MRD in prostate cancer
  • MRD in NSCLC and GI malignancies
  • MRD in gynecological cancer
    The Biology of MRD: Potential Relevance for Cancer Research Applications
  • The biology of metastasis in breast cancer: MRD as a model
  • Combined genome/transcriptosome analysis of single disseminated tumor cells
  • Genomic profiling and MRD: technology development and future perspectives
  • Expression signature of MRD in peripheral blood
  • Expression profiling of CTCs in breast and prostate cancer
  • Therapeutic targets in MRD
  • Glycobiology of solid tumors
  • Circulating endothelial cell analysis
  • Panel discussion: Single or multiple technologies for determining the biology of MRD
    Applications to Clinical Practice
  • The development of clinical trials evaluating MRD: Challenges and opportunities. The MRC trialists initiative

Conference Objectives: To report on the most relevant advances in the detection and characterization of minimal residual cancer in solid tumors.

Who Should Attend: Cancer researchers and clinicians

Registration Information: Please refer to www.ismrc.org

Conference Fees: $390- academic, $200 - student prior to July 15

Continuing Education: No


Is Ayurveda the Answer to Women’s Health Issues?
by The 4Wholeness Team
September 01, 2015

Related News

Flow Cytometry Indicates Treatment Response in AML

Sep 13, 2012

Assessment of minimal residual disease provides prognostic information for children with AML

Optimal margins for breast-conserving surgery for ductal carcinoma in situ less certain

Oct 28, 2010

Optimal margins for breast-conserving surgery for ductal carcinoma in situ less certain

Radioembolization +/− Bevacizumab Benefits CRC w/Mets

Jan 23, 2013

Findings in patients with metastasized cancer receiving radioembolization with/without bevacizumab